IRIS
STORTI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.322
EU - Europa 2.163
AS - Asia 1.211
AF - Africa 47
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 2
SA - Sud America 1
Totale 5.755
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.285
CN - Cina 916
SE - Svezia 531
IE - Irlanda 499
FI - Finlandia 365
IT - Italia 283
DE - Germania 194
TR - Turchia 154
SG - Singapore 98
UA - Ucraina 78
AT - Austria 53
CI - Costa d'Avorio 41
CA - Canada 36
RO - Romania 34
CZ - Repubblica Ceca 32
BE - Belgio 29
IN - India 26
FR - Francia 19
GB - Regno Unito 16
EU - Europa 9
NL - Olanda 9
IR - Iran 5
BG - Bulgaria 4
HK - Hong Kong 3
RU - Federazione Russa 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
CM - Camerun 2
ES - Italia 2
IL - Israele 2
LU - Lussemburgo 2
MD - Moldavia 2
NG - Nigeria 2
PT - Portogallo 2
SC - Seychelles 2
SM - San Marino 2
BN - Brunei Darussalam 1
BZ - Belize 1
CH - Svizzera 1
CO - Colombia 1
DK - Danimarca 1
HR - Croazia 1
KH - Cambogia 1
KZ - Kazakistan 1
PK - Pakistan 1
RS - Serbia 1
TW - Taiwan 1
Totale 5.755
Salva come PNG Salva come JPEG
Città #
Chandler 538
Dublin 499
Beijing 211
Ashburn 175
Jacksonville 157
Parma 148
Ann Arbor 145
Izmir 138
Nanjing 133
Dearborn 125
Shanghai 116
Princeton 90
New York 73
San Mateo 62
Kunming 57
Singapore 54
Vienna 53
Shenyang 52
Wilmington 50
Abidjan 41
Nanchang 38
Hebei 34
Toronto 33
Düsseldorf 32
Jiaxing 32
Jinan 30
Boardman 29
Bremen 29
Brussels 29
Tianjin 29
Helsinki 28
Brno 27
Hefei 25
Des Moines 23
Focsani 22
Los Angeles 22
Changsha 20
Seattle 16
Hangzhou 15
Kocaeli 15
Pune 14
Woodbridge 14
Norwalk 13
Munich 12
Redmond 12
Zhengzhou 12
Milan 11
Chengdu 9
Jesi 9
Taizhou 9
Guangzhou 8
Houston 8
Bologna 7
Fuzhou 7
Fairfield 6
Mestre 6
Palermo 6
Rockville 6
Chongqing 5
Modena 5
Ningbo 5
Borås 4
Cambridge 4
Chicago 4
Fremont 4
Haikou 4
Rho 4
Rome 4
Savignano sul Rubicone 4
Sofia 4
Timisoara 4
Washington 4
Ahmedabad 3
Catania 3
Cesena 3
Huizen 3
Leawood 3
Marseille 3
Nürnberg 3
Reggio Emilia 3
St Louis 3
Taiyuan 3
Wuhan 3
Arcevia 2
Baotou 2
Boston 2
Central 2
Chisinau 2
Cornaredo 2
Dubai 2
Edinburgh 2
Forest City 2
Geislingen an der Steige 2
Grafing 2
Jinhua 2
Lagos 2
London 2
L’Aquila 2
Madrid 2
Medesano 2
Totale 3.740
Salva come PNG Salva come JPEG
Nome #
Hypoxia and Hypoxia Inducible Factor (HIF)-1{alpha} in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment 101
Are the Myeloma bone microevironment cells tumoral or not? 99
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 97
Ammonium Production and Glutamine-Addiction of Myeloma Cells: New Attractive Targets in Multiple Myeloma 96
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 94
CC-4047 (Pomalidomide) inhibits multiple myeloma-induced osteoclast formation targeting RANKL in the bone marrow microenvironment 92
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients 91
Neurofibromatosis type I and multiple myeloma coexistence: A possible link? 91
Activation of non-canonical wnt pathway in human mesenchymal cells affects osteogenic differentiation: a potential target in Multiple Myeloma microenvironment 90
Hypoxia and hypoxia inducible factor (HIF)-1α in Multiple Myeloma patients: role in the angiogenic switch 90
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 88
The Immunomodulatory drugs Lenalidomide and Pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myeloma microenvironment targeting the expression of adhesion molecules 85
The homeobox gene HOXB7 regulates the production of pro-angiogenic molecole by myeloma cells and it is a target in myeloma-induced angiogenesis 85
HOXB7 is a key gene involved in Myeloma cell growth and Myeloma-induced angiogenesis in Multiple Myeloma patients 84
The IMID CC-4047 (Pomalidomide) inhibits myeloma-induced osteoclast formation 83
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma 82
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 81
Modulation of non canonical wnt5a/ror2 signaling pathway in human mesenchymal cells increases osteogenic differentiation counterbalancing the effect of myeloma cells 79
Novel targets for the treatment of relapsing multiple myeloma 79
Possible targets to treat myeloma-related osteoclastogenesis 78
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 76
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 76
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 76
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 76
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation 75
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma 75
Oxygen tension in the bone marrow (BM) of patients with malignant and indolent monoclonal gammopathy: role of hypoxia and hypoxia-inducible factor (HIF)-1{alpha} in the regulation of gene expression and pro-angiogenic profiles of CD138+ cells 73
HOXB7 is critically involved in Multiple Myeloma-induced angiogenic switch 73
The activation of wnt5a-mediated non canonical wnt signaling in human bone marrow osteoprogenitor cells increases osteoblastogenesis and counterbalances the inhibitory effect of myeloma cells on ror2/fzd5 expression 73
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 73
Bone microenvironment cells show a different pattern of gene expression profiling in relationship with the presence of osteolytic bone lesions in Multiple Myeloma patients 72
Non canonical wnt signal pathway (Wnt5a/ror2) activation stimulates the osteogenic differentiation process of bone mesenchymal cells being a potential target in multiple myeloma bone disease 70
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 70
Bone marrow monocyte / macrophage derived activin a mediates the osteoclastogenic effects of IL-3 in myeloma 69
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 69
Galectin-1 Is Highly Expressed By Myeloma Cells and the Bone Marrow Microenvironment and Its Suppression Delineates a New Therapeutic in Vitro and in Vivo Strategy in Multiple Myeloma 67
CC-Chemokine Ligand 20/Macrophage Inflammatory Protein-3A and CC-Chemokine Receptor 6 Are Overexpressed in Myeloma Microenvironment Related to Osteolytic Bone Lesions 66
A Mouse Model of Telomere Dysfunction Recapitulates Hallmark Features of Human Myelodysplastic Syndrome 66
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 66
Increased osteocyte apoptosis in Multiple Myeloma patients: a potential role in bone remodeling alterations related to osteolytic bone lesions 65
ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma 65
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 65
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 65
Myeloma cells inhibit the non-canonical wnt co-receptor ror2 in human mesenchymal/osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on mm-induced impairment of the osteogenic differentiation process 64
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 64
In vitro and In vivo evidences of osteocytes involvement in myeloma-induced osteolysis 63
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 63
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 63
Angiogenesis and multiple myeloma 63
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 63
Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients 62
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome 62
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 61
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 61
Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations 60
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 60
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo 59
ASSESSMENT OF THE INTERLABORATORY VARIABILITY AND ROBUSTNESS OF JAK2V617F MUTATION ASSAYS: A STANDARDIZATION STUDY INVOLVING A CONSORTIUM OF 19 ITALIAN LABORATORIES 59
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 58
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 58
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 56
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin? 55
Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma 54
Comet assay and prediction of clinical outcome after DNA-damaging drugs treatment 54
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 52
Role of Galectins in Multiple Myeloma. 51
The Myeloma Cells Escape from Bone Marrow to Skin Extramedullary Localization upon Bortezomib Resistance: Role of CXCR4 51
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 51
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 51
Relationship between skeletal involvement, cytogenetic features and bone marrow profiles of cytokines and chemokines in patients with monoclonal gammopathy 50
Relationship between presence of osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: role of chemokine (C-C motif) ligand 20 50
ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma 50
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 49
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 48
ILF2-YB1 INTERACTION MODULATES RNA SPLICING TO INDUCE RESISTANCE TO DNA-DAMAGING AGENTS IN 1Q21-AMPLIFIED MULTIPLE MYELOMA 48
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 48
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 47
IL3 Induces Osteoclastogenesis In Vivo and Is Modulated By Bone Marrow Monocyte / Macrophage Derived Activin A 46
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 46
Loss of stromal galectin-1 enhances multiple myeloma development: Emphasis on a role in osteoclasts 45
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells 44
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 44
Hypoxia-Inducible Factor (HIF)-1α Is a Therapeutic Target in Myeloma-Induced Angiogenesis 44
Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with Multiple Myeloma bone disease 42
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide 41
Is there a way to predict the clinical outcome of DNA strand breaks generating drugs? The case of calicheamicin 40
MYELOMA CELLS FROM THE BONE MARROW TO THE SKIN: HOW? 38
The impact of CD56 expression in smoldering myeloma patients on early progression 36
Detection of DNA strand breaks as individual predictive response to Gemtuzumab Ozogamicin in acute myeloid leukaemia 34
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 27
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 26
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 22
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 21
The transcriptomic profile of CD138+ cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged 21
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 12
CD38 expression by plasma cells in extramedullary multiple myeloma 10
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma 7
Totale 5.940
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.227
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.227
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.091 222 269 39 13 49 100 105 24 70 113 39 48
2020/2021464 33 37 20 10 76 10 26 23 110 32 50 37
2021/2022491 14 9 15 42 13 10 67 55 19 42 39 166
2022/20232.037 213 229 152 148 168 227 66 137 599 25 56 17
2023/2024776 30 71 14 19 55 215 77 34 21 46 51 143
2024/202549 49 0 0 0 0 0 0 0 0 0 0 0
Totale 5.940